# Endava plc: financial statements, quarterly

DAVA · NYSE · CIK 1656081 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/dava.md) · [Financials](/companies/dava/financials.md) · [Filings](/companies/dava/filings.md) · [Insiders](/companies/dava/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dava/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2020-03-31) | Q4 FY2020 (2020-06-30) |
| --- | --- | ---: | ---: |
| Revenue | $m | [92.2](/filings/0001656081-20-000016.md) | [90.5](/filings/0001656081-20-000016.md) |

- Revenue: ifrs-full:RevenueFromContractsWithCustomers

## Balance sheet

| Line item | Unit | period not labelled (2015-06-30) | period not labelled (2016-06-30) | period not labelled (2017-06-30) | FY2018 (2018-06-30) | FY2019 (2019-06-30) | FY2020 (2020-06-30) | FY2021 (2021-06-30) | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [13.4](/filings/0001656081-18-000004.md) | [12.9](/filings/0001656081-19-000025.md) | [23.6](/filings/0001656081-20-000016.md) | [15.0](/filings/0001656081-21-000053.md) | [70.2](/filings/0001656081-22-000042.md) | [101](/filings/0001656081-23-000041.md) | [69.9](/filings/0001656081-24-000037.md) | [163](/filings/0001656081-25-000039.md) | [165](/filings/0001656081-25-000039.md) | [62.4](/filings/0001656081-25-000039.md) | [59.3](/filings/0001656081-25-000039.md) |
| Current assets | $m | not reported | not reported | [65.8](/filings/0001656081-18-000004.md) | [68.1](/filings/0001656081-19-000025.md) | [137](/filings/0001656081-20-000016.md) | [187](/filings/0001656081-22-000042.md) | [190](/filings/0001656081-22-000042.md) | [328](/filings/0001656081-23-000041.md) | [348](/filings/0001656081-24-000037.md) | [268](/filings/0001656081-25-000039.md) | [282](/filings/0001656081-25-000039.md) |
| Total assets | $m | not reported | not reported | [106](/filings/0001656081-18-000004.md) | [151](/filings/0001656081-19-000025.md) | [223](/filings/0001656081-20-000016.md) | [357](/filings/0001656081-22-000042.md) | [469](/filings/0001656081-22-000042.md) | [622](/filings/0001656081-23-000041.md) | [770](/filings/0001656081-24-000037.md) | [1,009](/filings/0001656081-25-000039.md) | [936](/filings/0001656081-25-000039.md) |
| Current liabilities | $m | not reported | not reported | [54.8](/filings/0001656081-18-000004.md) | [71.1](/filings/0001656081-19-000025.md) | [54.2](/filings/0001656081-20-000016.md) | [76.5](/filings/0001656081-22-000042.md) | [103](/filings/0001656081-22-000042.md) | [128](/filings/0001656081-23-000041.md) | [121](/filings/0001656081-24-000037.md) | [154](/filings/0001656081-25-000039.md) | [122](/filings/0001656081-25-000039.md) |
| Shareholders' equity | $m | [26.0](/filings/0001656081-18-000004.md) | [29.8](/filings/0001656081-19-000025.md) | [48.7](/filings/0001656081-20-000016.md) | [69.6](/filings/0001656081-21-000053.md) | [164](/filings/0001656081-22-000042.md) | [232](/filings/0001656081-23-000041.md) | [296](/filings/0001656081-24-000037.md) | [433](/filings/0001656081-25-000039.md) | [571](/filings/0001656081-25-000039.md) | [639](/filings/0001656081-25-000039.md) | [583](/filings/0001656081-25-000039.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 55,718,456 at 2021-06-30, from the cover of the [20-F filed 2021-09-28](/filings/0001656081-21-000053.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.